ProMIS Neurosciences (PMN) Registration Filing summary

Company overview and business model

• Applies a patented technology platform to develop antibody therapies and vaccines for neurodegenerative and protein-misfolding diseases, focusing on Alzheimer's, multiple system atrophy, and ALS.

• Lead product candidate PMN310 targets toxic amyloid-beta oligomers in Alzheimer's and is in Phase 1b clinical trials.

• Pipeline includes PMN267 for ALS and PMN442 for synucleinopathies, with additional preclinical programs and machine learning-based discovery.

• Operations have been primarily financed through public and private placements of equity and convertible debt.

Financial performance and metrics

• As of June 30, 2025, 32,689,190 common shares were outstanding, with additional options, warrants, and pre-funded warrants potentially increasing dilution.

• Net tangible book value at June 30, 2025 was approximately $(0.4) million, or $(0.01) per share.

• After the offering, as adjusted net tangible book value would be approximately $17.6 million, or $0.28 per share, with immediate dilution of $0.35 per share to new investors at an assumed offering price of $0.628.

Use of proceeds and capital allocation

• Net proceeds will be used to advance clinical development of PMN310, for working capital, and general corporate purposes, including R&D, manufacturing, regulatory, clinical trials, acquisitions, investments, business combinations, and potential debt repayment.

• Management retains broad discretion over allocation of net proceeds.